Immunology and Microbiology
COVID-19
100%
Lupus Anticoagulant
59%
Antiphospholipid Antibody
40%
C-Reactive Protein
13%
Time
13%
Titer
9%
Pregnancy
4%
Morbidity
4%
Daboia russellii
4%
Clotting Time
4%
Anticoagulation
4%
Medicine and Dentistry
Lupus Anticoagulant
59%
Patient
36%
Inpatient
18%
Thrombosis
13%
C Reactive Protein
13%
Assay
13%
Anticoagulant Therapy
9%
Heparin
9%
False Positive Result
9%
Direct Oral Anticoagulant
9%
Morbidity
4%
Antithrombotic
4%
Pregnancy
4%
Low Molecular Weight Heparin
4%
Infection
4%
Silicon Dioxide
4%
Critical Appraisal
4%
Anticoagulation
4%
Phospholipid
4%
Coagulopathy
4%
Vitamin K Antagonist
4%
Dilute Russell's Viper Venom Time
4%
Pathology
4%
Nursing and Health Professions
Lupus Anticoagulant
59%
C Reactive Protein
13%
Thrombosis
13%
Publication
13%
Assay
13%
Heparin
9%
Activated Partial Thromboplastin Time
9%
Anticoagulant Therapy
9%
False Positive Result
9%
Hospital
4%
Infection
4%
Anticoagulation
4%
Morbidity
4%
Critical Appraisal
4%
Anticoagulant Agent
4%
Antivitamin K
4%
Blood Clotting Time
4%
Syndrome
4%
Low Molecular Weight Heparin
4%
Laboratory
4%
Silicon Dioxide
4%
Phospholipid
4%
Blood Clotting Disorder
4%
Pharmacology, Toxicology and Pharmaceutical Science
Lupus Anticoagulant
59%
C Reactive Protein
13%
Thrombosis
13%
Heparin
9%
Confounder
9%
Low Molecular Weight Heparin
4%
Morbidity
4%
Anticoagulant Agent
4%
Infection
4%
Silicon Dioxide
4%
Phospholipid
4%
Antivitamin K
4%
Blood Clotting Disorder
4%
Clotting Time
4%
Syndrome
4%
Neuroscience
Lupus Anticoagulant
59%
Anticoagulant
18%
C-Reactive Protein
13%
Thromboplastin
9%
Vitamin K Antagonist
4%
Low Molecular Weight Heparin
4%
Coagulopathies
4%
Phospholipid
4%